Outcome of Patients with Pathological Tumor Stage T3 Urothelial Carcinoma of the Bladder following Radical Cystectomy in a Single-Center Series with 116 Patients by Breyer, Johannes et al.
E-Mail karger@karger.com
 Original Paper 
 Urol Int 2014;93:311–319 
 DOI: 10.1159/000360483 
 Outcome of Patients with Pathological Tumor 
Stage T3 Urothelial Carcinoma of the Bladder 
following Radical Cystectomy in a Single-Center 
Series with 116 Patients 
 Johannes Breyer a    Stefan Denzinger a    Wolfgang Otto a    Johannes Bründl a    
Michael Gierth a    Hans-Martin Fritsche a    Wolfgang Rößler a    Wolf F. Wieland a    
Christian Giedl b    Ferdinand Hofstädter b    Peter Rubenwolf c    
Maximilian Burger a    Atiqullah Aziz a  
 a  Department of Urology, Caritas St. Josef Medical Center, and  b  Department of Pathology, University of Regensburg, 
 Regensburg , and  c  Department of Urology, Johannes Gutenberg University of Mainz Medical School,  Mainz , Germany
 
cific (CSS) and overall survival (OS), respectively.  Results: No 
significant differences were found addressing clinicopatho-
logical data and substaged pT3. In multivariable Cox regres-
sion models, lymph node involvement was an independent 
predictor for PFS (p < 0.001), CSS (p < 0.001) and OS (p = 
0.002), respectively. Lymphovascular invasion (LVI) signifi-
cantly influenced PFS (p = 0.016). ASA score 3/4 indepen-
dently predicted CSS (p = 0.049) and OS (p = 0.032). Neither 
pT3 substages nor E-cad expression were significant prog-
nosticators for survival.  Conclusions: In pT3 UCB patients 
with ASA 3/4, positive lymph node status and/or presence of 
LVI, administration of chemotherapy should be considered 
due to the high risk of poor oncological outcome. The im-
munohistochemical marker E-cad was not an independent 
predictor.  © 2014 S. Karger AG, Basel 
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 Abstract 
 Objective: Outcome prediction of pT3 urothelial carcinoma 
of the bladder (UCB) after radical cystectomy (RC) remains 
challenging. The objective of our study was to determine 
high-risk patients with poor survival outcome in a heteroge-
neous group substaged pT3 who might profit from early ad-
juvant chemotherapy.  Materials and Methods: We com-
piled clinicopathological and immunohistochemical data of 
E-cadherin (E-cad) expression in 116 patients with pT3 UCB 
after RC in our single-center series. Multivariable Cox regres-
sion models including substaged pT3 established clinico-
pathological features, and the expression of the predictive 
immunohistochemical feature E-cad was used to identify in-
dependent predictors on progression-free (PFS), cancer-spe-
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 Introduction 
 Urothelial carcinoma of the bladder (UCB) represents 
one of the most common malignancies of the urinary 
tract and is the fourth most common cancer in men  [1] . 
Roughly 25% of the initially diagnosed UCB are already 
in a muscle-invasive or metastatic stage and are therefore 
associated with a poor prognosis  [2] . To date, the gold 
standard in surgical therapy of high-risk non-muscle-in-
vasive and muscle-invasive UCB remains radical cystec-
tomy (RC) and pelvic lymph node dissection  [3] . 
 In 1997, the American Joint Committee on Cancer 
(AJCC) modified the TNM staging system for bladder 
cancer substaging pathological tumor (pT) stage 3 into 
microscopic (pT3a) and macroscopic (pT3b) infiltra-
tion of the perivesical fat  [4] . Subsequently, several au-
thors presented their findings addressing the prognostic 
impact of pT3a versus pT3b tumors  [5–11] . However, 
data addressing this issue is far from conclusive and still 
under debate. While some study groups were unable to 
detect any difference in survival  [5–8] , others demon-
strated a prognostic relevance of the substaging revision 
and integrated the substaged pT3 in assessment tools 
 [9–11] . 
 In outcome prediction for UCB, the calcium-depen-
dent transmembrane glycoprotein E-cadherin (E-cad) is 
ascribed a major role as tumor invasion suppressor  [12] . 
A decrease or lack of E-cad expression is associated with 
an advanced stage of UCB with higher risk of regional 
lymph node metastasis and inferior survival rates  [13] . 
 Therefore, the aim of the present study was to identify 
predictors of outcome in the heterogeneous population 
of pT3 UCB within a range of established clinicopatho-
logical features and E-cad expression in a single-center 
cohort following RC based on statistically rigorous analy-
sis. Thus, we sought to unmask pT3 UCB patients at an 
increased risk of poor cancer-specific (CSS) or progres-
sion-free survival (PFS), which would allow us to perform 
a better stratification for the administration of adjuvant 
treatment and tailored surveillance after RC. 
 Patients and Methods 
 Study Population 
 After obtaining local ethics committee approval, the clinico-
pathological data of 429 consecutive patients undergoing RC and 
pelvic lymph node dissection for high-risk non-muscle-invasive or 
muscle-invasive UCB by selected surgeons at one academic uro-
logical center from 1989 to 2010 were assessed. All pT3 patients
(n = 116) were extracted from the database. None of the patients 
received neoadjuvant or perioperative radio-/chemotherapy. 
 Pathological Evaluation 
 All of the RC specimens were analyzed via central pathologi-
cal review by dedicated genitourinary pathologists at our institu-
tion. The pathological staging of all specimens was reviewed and 
updated according to the 2002 TNM criteria; the WHO classifi-
cation of 1973 was used for pathological grading. Lymphovascu-
lar invasion (LVI) was defined as the unequivocal presence of 
tumor cells within an endothelium-lined space with no underly-
ing muscular walls  [14] . A positive soft tissue surgical margin 
was defined as tumor at inked areas of soft tissue on the RC spec-
imen. Urethral or ureteral margin status was not considered a 
margin.
 Immunohistochemistry 
 Immunohistochemical staining for E-cad (1: 50, No. M3612, 
clone NCH-38; Dako, Glostrup, Denmark) was conducted in all of 
the patients. Immunohistochemical evaluation was performed 
with a polymer-based detection system following optimized epi-
tope retrieval. Sections were deparaffinized and rehydrated using 
deionized water. Afterwards, sections were heated in citrate buffer 
(pH 6.0) using an electric pressure cooker for 3 min and cooled for 
10 min before staining. The sections were then screened using an 
optical microscope to evaluate the E-cad staining pattern address-
ing homogeneity. Then, localization of E-cad was classified as nu-
clear, cytoplasmic or membrane associated. Finally, intensity was 
described as absent (–), weak (+), mild (++) or strong (+++). 
 Follow-Up 
 The median follow-up of patients alive at the end of the inves-
tigation was 15 months (interquartile range, IQR 7–32). Follow-
up was performed according to current guidelines  [3] . Patients 
were generally screened postoperatively at least every 3–4 months 
within the 1st year, semiannually for the 2nd year and annually 
thereafter. Follow-up consisted of physical examination and se-
rum chemistry evaluation. Diagnostic imaging of the upper uri-
nary tract and chest X-rays were done at least annually or when 
clinically indicated. Additional radiographic evaluation, such as 
bone scan and/or computerized tomography, was conducted at 
the treating physician’s discretion. Disease progression was de-
fined as tumor relapse in the operative field, regional lymph 
nodes and/or distant metastasis. Urothelial carcinoma occurring 
in the ureter and/or urethra was regarded as a metachronous tu-
mor and not coded as disease progression. Cause of death was 
determined by the treating physician, by chart review corrobo-
rated by death certificates or by death certificates alone  [15] . All 
patients who were coded as having died of cancer had previous 
disease progression. Follow-up was recorded from the date of 
surgery until the last physical examination or death. The end 
points of the study were PFS, CSS and overall survival (OS), re-
spectively.
 Statistical Analysis 
 The Shapiro-Wilk normality test was used to analyze normal 
distribution of continuous variables. Continuous variables are 
shown as medians with IQR. The Wilcoxon rank sum (Mann-
Whitney U) test was applied for nonnormally distributed vari-
ables. Comparisons between categorical variables were conducted 
using Fisher’s exact test and the χ 2 test.
 Survival rates were estimated using the Kaplan-Meier method; 
the log-rank test was utilized for comparison of survival curves. 
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Multivariable Cox regression models calculated in enter mode 
were performed to evaluate the influence of substaged pT3 UCB, 
the clinicopathological parameters age, gender, the American As-
sociation of Anesthesiologist score (ASA), carcinoma in situ, soft 
tissue surgical margins, lymph node involvement (LNI), LVI and 
E-cad expression on disease progression, cancer-specific and all-
cause mortality, respectively. The impact of the variables in the 
Cox models was assessed using the area under the receiver-oper-
ating characteristic curves. 
 Statistical analyses were performed with SPSS ® Statistics 20 
(SPSS, IBM Corp., Armonk, N.Y., USA) and R (version 3.0.0; The 
R Foundation for Statistical Computing, Vienna, Austria). Report-
ed p values are two sided with the statistical significance level set 
at p  ≤ 0.05.
 Results 
 Study Population 
 A total of 74 patients (63.8%) had pT3a and 42 patients 
(36.2%) pT3b. Their median age was 73 years (IQR 63–
77); 87 (75%) patients were male and 29 (25%) female. No 
statistically significant differences were found in clinico-
pathological features and E-cad expression in association 
with tumor substages ( table  1 ), respectively. Most fre-
quent urinary diversions accompanying RC were ileal 
conduit (59%), ileal neobladder (30%) and Indiana pouch 
(4.5%).
 E-cad Expression in Stage pT3 UCB 
 E-cad was expressed in 97 patients (83.6%); 19 patients 
(16.4%) did not express E-cad in the specimens analyzed. 
Intensity of E-cad staining in patients expressing E-cad 
was weak (+), mild (++) and strong (+++) in 20, 48 and 
32% of the patients, respectively. About 94% of these pa-
tients showed a strict membranous expression of E-cad, 
and in 6.2% E-cad expression was only cytoplasmic 
( fig. 1 ). Neither intensity nor location of E-cad expression 
was significantly associated with any analyzed clinical or 
histopathological parameter (data not shown). 
 Clinical Outcomes 
 During follow-up, disease recurrence was observed in 
60 patients (51.7%), cancer-specific mortality in 50 pa-
tients (43.1%), and 71 patients (61.2%) died due to all-
cause mortality. In Kaplan-Meier analyses, both LNI (p < 
0.001) and LVI (p < 0.001) were significantly associated 
with decreased PFS ( fig. 2 ). With regard to CSS ( fig. 3 ) 
and OS ( fig.  4 ) estimates, ASA 3/4 (p = 0.020 and p = 
0.003), LNI (p < 0.001 and p = 0.008) and LVI (p < 0.001 
and p = 0.001), respectively, were associated with poor 
survival. 
 Table 1.  Clinicopathological and immunohistochemical charac-
teristics of 116 patients with pT3 UCB after RC
Parameter All 
patients
(n = 116)
 pT3
 pT 3a pT3b p 
value (n = 74) (n = 42)
Median age, years
IQR
73
63 – 77
70
64 – 77
68
60 – 82
0.646
Gender   0.512
Male 87 (75.0) 57 (49.1) 30 (25.9)
Female 29 (25.0) 17 (14.7) 12 (10.3)
ASA 0.298
1 23 (20.7) 15 (13.5) 8 (7.2)
2 44 (39.6) 31 (27.9) 13 (11.7)
3 43 (38.7) 23 (20.7) 20 (18.0)
4 1 (0.9) 1 (0.9) 0 (0.0)
Lymph node status 0.330
Node-negative 66 (56.9) 45 (38.8) 21 (18.1)
Node-positive 50 (43.1) 29 (25.0) 21 (18.1)
LVI 0.697
Absent 51 (44.0) 34 (29.3) 17 (14.7)
Present 65 (56.0) 40 (34.5) 25 (21.6)
E-cad expression 0.436
Absent 19 (16.4) 14 (12.1) 5 (4.3)
Present 97 (83.6) 60 (51.7) 37 (31.9)
E-cad intensity 0.679
– 19 (16.4) 14 (12.1) 5 (4.3)
+ 20 (17.2) 11 (9.5) 9 (7.8)
++ 46 (39.7) 29 (25.0) 17 (14.7)
+++ 31 (26.7) 20 (17.2) 11 (9.5)
E-cad localization 1.000
Cytoplasmic 6 (6.2) 4 (4.1) 2 (2.1)
Membranous 91 (93.8) 56 (57.7) 35 (36.1)
Carcinoma in situ 0.053
Absent 60 (51.7) 33 (28.4) 27 (23.3)
Present 56 (48.3) 41 (35.3) 15 (12.9)
Soft tissue surgical management 0.202
Negative 105 (90.5) 69 (59.5) 36 (31.0)
Positive 11 (9.5) 5 (4.3) 6 (5.2)
Urinary diversion 0.105
Ileal conduit 71 (61.2) 42 (36.2) 29 (25.0)
Indiana pouch 5 (4.3) 4 (3.4) 1 (0.9)
Ileal neobladder 33 (28.4) 24 (20.7) 9 (7.8)
Ureterocutaneostomy 3 (2.6) 3 (2.6) 0 (0.0)
Others 4 (3.4) 1 (0.9) 3 (2.6)
Administration of adjuvant chemotherapy 0.799
Absent 96 (82.8) 62 (53.4) 34 (29.3)
Present 20 (17.2) 12 (10.3) 8 (6.9)
Figures in parentheses are percentages.
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 In multivariable Cox regression models calculated in 
enter mode, LNI (hazard ratio, HR 3.716, p < 0.001), LVI 
(HR 2.299, p = 0.016) and administration of adjuvant che-
motherapy (HR 0.36, p = 0.010) significantly impacted 
disease progression. CSS and OS were independently in-
fluenced by ASA 3/4 (HR 1.82, p = 0.049, and HR 1.72,
p = 0.032), LNI (HR 4.57, p < 0.001, and HR 2.57, p = 
0.002) and administration of adjuvant chemotherapy 
(HR 0.28, p = 0.005, and HR 0.37, p = 0.009), respectively 
( table 2 ). The area under the curve values for the models 
addressing disease progression, CSS and OS were 0.740, 
0.724 and 0.701, respectively. 
Cytoplasmic: 6% Membranous: 94%
Weak: 20% Mild: 48% Strong: 32%
 Fig. 1. Localization, extent and frequency of E-cad immunohistochemical staining in stage pT3 UCB (magnification: ×400). 
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 Fig. 2. Kaplan-Meier analysis estimating PFS according to LNI ( a ) and the absence (LVI–) or presence (LVI+) of LVI ( b ). N– = Node-
negative; N+ = node-positive. The log-rank test was employed. 
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 Discussion 
 The aim of the present study was to assess outcome 
predictors of patients suffering from pT3 UCB. Since in 
some trials, adjuvant chemotherapy is routinely adminis-
tered [16] , we sought to identify patients at high risk for 
poor oncological outcome who might profit from the ad-
ministration of adjuvant chemotherapy and/or close sur-
veillance after RC. 
 Since the AJCC/TNM substaging of pT3 UCB into mi-
croscopic (pT3a) and macroscopic (pT3b) infiltration of 
perivesical fat in 1997, this issue has formed the basis for 
many debates on bladder cancer in terms of the prognos-
tic potential of the subdivided stage. The findings of our 
investigation demonstrate that regardless of LNI, pT3 
substage has no independent impact on outcome after RC 
regarding progression and mortality. In line with our re-
sults, Quek et al.  [5] found no statistical differences in 69 
patients with pT3a versus 167 with pT3b UCB during a 
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 Fig. 3. Kaplan-Meier analysis estimating CSS according to ASA 3/4 
( a ), LNI ( b ) and the absence (LVI–) or presence (LVI+) of LVI ( c ). 
N– = Node-negative; N+ = node-positive. The log-rank test was 
employed. 
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median follow-up of roughly 9 years. Bastian et al.  [6] 
from the Bladder Cancer Research Consortium initially 
described a significant difference in recurrence and mor-
tality between 210 patients staged pT3a versus pT3b, but 
this effect was evened out when adjusted for lymph node 
metastases. Tilki et al.  [9] showed no statistical differenc-
es in outcome regarding pT3 substage in 808 patients. 
However, after inclusion of merely lymph node-negative 
patients (n = 456), gross tumor infiltration had a signifi-
cant impact (p = 0.020 vs. 0.048) on 5-year recurrence-
free survival (60.7 vs. 47.9%) and CSS (64.4 vs. 55.0%)  [9] . 
In order to diminish the potential bias of LNI, we calcu-
lated the same models after excluding all patients with 
positive lymph nodes (n = 50) using multivariable Cox 
regression models. Similar to previous studies addressing 
this issue  [5, 7, 8] , pT3 substage in our node-negative co-
hort of 66 patients had no independent impact on sur-
vival (data not shown). 
 LNI (p  ≤ 0.002) significantly affected all of our end 
points, while LVI (p = 0.016) had an independent effect 
0.8
0.6
0.4
0.2
1.0
0
Pr
ob
ab
ili
ty
 o
f O
S
ASA 1/2
ASA 3/4
p = 0.003
483624120 60
Time after RC (months)a
483624120 60
Time after RC (months)b
0.8
0.6
0.4
0.2
1.0
0
Pr
ob
ab
ili
ty
 o
f O
S
N–
N+
p = 0.008
LVI–
LVI+
p = 0.001
0.8
0.6
0.4
0.2
1.0
0
Pr
ob
ab
ili
ty
 o
f O
S
483624120 60
Time after RC (months)c
 Fig. 4. Kaplan-Meier analysis estimating OS according to ASA 3/4 
( a ), LNI ( b ) and the absence (LVI–) or presence (LVI+) of LVI ( c ). 
N– = Node-negative; N+ = node-positive. The log-rank test was 
employed. 
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on PFS. In our calculations, LVI and LNI were both test-
ed for collinearity and displayed a φ value <0.55 (p < 
0.001), thus allowing us to integrate both of the features 
in the same model. In line with Quek et al.  [5] , we could 
not see a significant association between the distribution 
of tumor substage and LNI (p = 0.33). In the study by 
Tilki et al.  [9] , both LVI (p  ≤ 0.014) and LNI (p < 0.001) 
had a significant impact on disease recurrence and CSS, 
respectively, regardless of lymph node status. The value 
of LVI in outcome prediction in pT3 UCB was utilized 
through its integration into prognostic assessment tools 
 [10, 11] . Currently, LNI remains the strongest predictor 
of outcome in UCB regardless of stage. Our findings 
mirror those of the vast majority of studies in UCB as-
cribing positive nodal stage a poor outcome after RC 
 [17–22] .
 ASA was shown to be a strong predictor of CSS and OS 
in our cohort. In contrast to all of the studies that address 
the matter of outcome prediction in substaged pT3 UCB 
published to date, we were able to demonstrate that ASA 
3/4 is an independent predictor of survival for the first 
time. Comorbidity plays a large role in the treatment and 
follow-up of patients with RC due to UCB  [23] . Mayr et 
al.  [23] investigated the impact of severe comorbidity and 
performance indices on outcome in patients with UCB 
after RC with regard to cancer-independent mortality. In 
their multicenter multinational study, they found a sig-
nificant impact of ASA on cancer-independent mortality 
(p = 0.001) in Cox regression models. In our population, 
ASA 3/4 patients had a 1.7-fold higher risk of all-cause 
mortality (p = 0.032) and a 1.8-fold higher risk of cancer-
specific mortality (p = 0.049). Thus, pT3 patients with 
ASA 3/4 should be monitored closely after RC, with mod-
ification to surveillance as required. 
 In addition to the established clinicopathological 
markers addressing outcome prediction in UCB patients 
after RC, we added the immunohistochemical marker
E-cad to our calculations due to its potential predictive 
capacity. Decreased E-cad expression is associated with a 
high risk of tumor progression  [24] and poor CSS, respec-
tively  [25] . However, several studies failed to find an in-
dependent impact of the E-cad expression pattern on the 
prognosis of UCB patients  [26, 27] . Expression of E-cad 
did not influence prognostic outcome after RC in our 
population of pT3 UCB both with and without taking 
lymph node-negative patients into account. A potential 
explanation could be found in the differences in immu-
nohistochemical staining and analysis procedures, since 
our study only classified specimens with a strict loss of 
E-cad as E-cad negative. Nevertheless, we currently have 
no explanation for the lack of impact of E-cad on out-
come after RC.
 The administration of adjuvant chemotherapy could 
benefit patients with locally advanced UCB, but is gener-
ally recommend within clinical trials  [3] . However, our 
study could not find a significant benefit of adjuvant che-
motherapy administration on survival (data not shown), 
in agreement with the findings of Tilki et al.  [9] . Despite 
the small number of patients receiving adjuvant chemo-
therapy (n = 20), we were able to determine an indepen-
dent influence of adjuvant chemotherapy on outcome. 
We therefore recommend consideration of adjuvant che-
 Table 2.  Multivariable Cox regression models addressing PFS, CSS and OS in 116 patients with pT3 UCB after RC
Parameter PFS CSS OS
 HR 95% CI p HR  95% CI p HR 95% CI p
Age (cont.) 1.011 0.980 – 1.043 0.486 1.030 0.994 – 1.068 0.107 1.027 0.998 – 1.057 0.072
Female gender (ref.: male) 0.917 0.490 – 1.716 0.786 1.080 0.557 – 2.095 0.820 0.930 0.530 – 1.632 0.800
ASA 3/4 (ref.: ASA 1/2) 1.495 0.854 – 2.618 0.159 1.823 1.003 – 3.313 0.049 1.720 1.047 – 2.825 0.032
pT3a vs. pT3b 0.905 0.489 – 1.672 0.749 0.978 0.507 – 1.890 0.948 1.248 0.738 – 2.111 0.409
CIS (present vs. absent) 0.597 0.333 – 1.069 0.083 0.669 0.361 – 1.239 0.201 0.984 0.592 – 1.637 0.952
Positive LN status (ref.: negative LN status) 3.716 1.833 – 7.534 <0.001 4.568 2.142 – 9.740 <0.001 2.568 1.405 – 4.694 0.002
Small tissue surgical margin (present vs. absent) 1.322 0.580 – 3.013 0.506 0.965 0.357 – 2.605 0.944 0.769 0.320 – 1.849 0.557
LVI (present vs. absent) 2.299 1.164 – 4.539 0.016 1.713 0.842 – 3.486 0.138 1.463 0.827 – 2.587 0.191
E-cad expression (present vs. absent) 1.041 0.396 – 2.735 0.935 0.637 0.238 – 1.708 0.371 0.636 0.301 – 1.341 0.234
Administration of adjuvant chemotherapy 0.356 0.162 – 0.779 0.010 0.278 0.113 – 0.686 0.005 0.365 0.171 – 0.780 0.009
(absent vs. present)
 CIS = Carcinoma in situ; LN = lymph node.
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motherapy in patients with positive lymph node status 
and/or presence of LVI. Moreover, information on the 
presence of LVI, ASA status and clinically suspected pos-
itive lymph node stage at the time of the last transurethral 
resection of bladder tumor before RC might facilitate the 
stratification of patients for neoadjuvant chemotherapy. 
Further studies are warranted, preferably prospective 
studies, to address this issue.
 Our study is not devoid of limitations. First and fore-
most, there are limitations inherent to retrospective stud-
ies. Another limitation is the lack of neoadjuvant chemo-
therapy administration despite recent recommendations 
 [3] , which could compromise comparability to future 
data. The major limitation is the cohort size included in 
our investigation. However, this was a single-center study 
with a small of number of experienced surgeons and stan-
dard surgery procedures established over years. Further-
more, a central pathology review was not performed, thus 
minimizing the potential bias of an interobserver vari-
ability between pathologists. Moreover, all surgeons and 
pathologists at our institution are dedicated to the man-
agement of RC.
 Conclusions 
 The findings of our study demonstrate that both pT3 
substage and E-cad expression did not impact on out-
come prediction after RC for patients with pT3 UCB. In 
clinical decision making for this heterogeneous group of 
UCB patients, we strongly recommend taking positive 
lymph node status, LVI and ASA 3/4 into account for the 
administration of adjuvant chemotherapy and modifica-
tion of surveillance after RC. Our results ideally need to 
be validated within a robust, prospective cohort.
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